This preprint is under consideration at Thrombosis Journal. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Case report
Sufana Shikdar
The University of Oklahoma Stephenson Cancer Center
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: In the recent COVID19 pandemic, patients with hematological malignancies were considered high risk for severe disease. Limited data is available regarding course of COVID19 infection in this subgroup.
Case Presentation: We describe a case of 32-year‐old man with paroxysmal nocturnal hemoglobinuria (PNH) undergoing treatment with ravulizumab (Ultomiris) who presented with COVID19 infection. He experienced only mild symptoms and had a rapid recovery from COVID19 infection.
Conclusion: This case may demonstrate the beneficial effects of ravulizumab on complement mediated inflammatory damage linked with COVID19 infection especially in PNH patients.
Keywords
COVID19, Paroxysmal nocturnal hemoglobinuria, complement inhibitor
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version (no preprint)
Posted 03 Oct, 2021
Reviewer #2 agreed
On 03 Oct, 2021
Review #2 received
Received 03 Oct, 2021
Editorial decision: Minor revision
On 03 Oct, 2021
Reviewer #1 agreed
On 02 Oct, 2021
Review #1 received
Received 02 Oct, 2021
First submitted
On 28 Sep, 2021
Editor assigned
On 27 Sep, 2021
Reviewers invited
Invitations sent on 27 Sep, 2021
Submission checks complete
On 27 Sep, 2021
Editor invited
On 27 Sep, 2021
This version was not preprinted
Version (no preprint)
Posted 29 Jun, 2021
This version was not preprinted
Version (no preprint)
Posted 25 May, 2021
This version was not preprinted
Version (no preprint)
Posted 25 May, 2021
This version was not preprinted
Version (no preprint)
Posted 25 May, 2021
This version was not preprinted
Version (no preprint)
Posted 25 May, 2021
This version was not preprinted
Version (no preprint)
Posted 25 May, 2021
This version was not preprinted
Version (no preprint)
Posted 19 May, 2021
Review #1 received
Received 03 Jul, 2021
Reviewer #1 agreed
On 27 Jun, 2021
Reviewers invited
Invitations sent on 27 Jun, 2021
Editor assigned
On 19 May, 2021
Submission checks complete
On 19 May, 2021
Editor invited
On 19 May, 2021
First submitted
On 18 May, 2021
This version was not preprinted
Version (no preprint)
Posted 29 Sep, 2020
This version was not preprinted
Version 1
Posted 29 Sep, 2020
No community comments so far
Review #1 received
Received 25 Mar, 2021
Reviewer #1 agreed
On 11 Mar, 2021
Reviewers invited
Invitations sent on 08 Nov, 2020
First submitted
On 24 Sep, 2020
Editor assigned
On 24 Sep, 2020
Submission checks complete
On 23 Sep, 2020
Editor invited
On 23 Sep, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Thrombosis Journal. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Case report
Sufana Shikdar
The University of Oklahoma Stephenson Cancer Center
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version (no preprint)
Posted 03 Oct, 2021
Reviewer #2 agreed
On 03 Oct, 2021
Review #2 received
Received 03 Oct, 2021
Editorial decision: Minor revision
On 03 Oct, 2021
Reviewer #1 agreed
On 02 Oct, 2021
Review #1 received
Received 02 Oct, 2021
First submitted
On 28 Sep, 2021
Editor assigned
On 27 Sep, 2021
Reviewers invited
Invitations sent on 27 Sep, 2021
Submission checks complete
On 27 Sep, 2021
Editor invited
On 27 Sep, 2021
This version was not preprinted
Version (no preprint)
Posted 29 Jun, 2021
This version was not preprinted
Version (no preprint)
Posted 25 May, 2021
This version was not preprinted
Version (no preprint)
Posted 25 May, 2021
This version was not preprinted
Version (no preprint)
Posted 25 May, 2021
This version was not preprinted
Version (no preprint)
Posted 25 May, 2021
This version was not preprinted
Version (no preprint)
Posted 25 May, 2021
This version was not preprinted
Version (no preprint)
Posted 19 May, 2021
Review #1 received
Received 03 Jul, 2021
Reviewer #1 agreed
On 27 Jun, 2021
Reviewers invited
Invitations sent on 27 Jun, 2021
Editor assigned
On 19 May, 2021
Submission checks complete
On 19 May, 2021
Editor invited
On 19 May, 2021
First submitted
On 18 May, 2021
This version was not preprinted
Version (no preprint)
Posted 29 Sep, 2020
This version was not preprinted
Version 1
Posted 29 Sep, 2020
No community comments so far
Review #1 received
Received 25 Mar, 2021
Reviewer #1 agreed
On 11 Mar, 2021
Reviewers invited
Invitations sent on 08 Nov, 2020
First submitted
On 24 Sep, 2020
Editor assigned
On 24 Sep, 2020
Submission checks complete
On 23 Sep, 2020
Editor invited
On 23 Sep, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: In the recent COVID19 pandemic, patients with hematological malignancies were considered high risk for severe disease. Limited data is available regarding course of COVID19 infection in this subgroup.
Case Presentation: We describe a case of 32-year‐old man with paroxysmal nocturnal hemoglobinuria (PNH) undergoing treatment with ravulizumab (Ultomiris) who presented with COVID19 infection. He experienced only mild symptoms and had a rapid recovery from COVID19 infection.
Conclusion: This case may demonstrate the beneficial effects of ravulizumab on complement mediated inflammatory damage linked with COVID19 infection especially in PNH patients.
Figure 1
Loading...